Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. - Wikidata - wikimedia - TriplyDB

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

http://www.wikidata.org/entity/Q52007706

about

Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Pain management strategies for neuropathic pain in Fabry disease--a systematic review Agalsidase alfa: a review of its use in the management of Fabry disease Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests Stroke and Fabry disease.Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).Update on role of agalsidase alfa in management of Fabry disease.Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience Agalsidase benefits renal histology in young patients with Fabry disease.Novel therapeutic targets for the treatment of Fabry disease.Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease.An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Assessment of renal pathology and dysfunction in children with Fabry disease.Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.Early therapeutic intervention in females with Fabry disease?Early cardiac changes in children with anderson-fabry disease.Renal complications of Fabry disease in children Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease Fabry disease in children and the effects of enzyme replacement treatment.Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.Fabry disease: a review of current management strategies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Safety of agalsidase alfa in patients with Fabry disease under 7 years.Fabry disease, enzyme replacement therapy and the significance of antibody responses.Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Fabry disease in infancy and early childhood: a systematic literature review.Perspectives in Pediatric Pathology, Chapter 21. Testicular Pathology in Heritable Metabolic Disease.Fabry's disease: an example of cardiorenal syndrome type 5.Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease.Urine bikunin as a marker of renal impairment in Fabry's disease.

P2860

Q24200877-F3A196FF-0E7A-4901-BEC1-DA46ABE8B9F4 Q24235483-1B02A678-E484-407E-989A-F1135DD58FF3 Q24650910-E23858F5-3867-4486-B599-9FA2F8578FE7 Q26471010-BA6E5F0E-8D14-496A-8676-EF765A68CF53 Q26766561-E3A2E296-F270-4641-B28C-8F3B0246E217 Q28274194-658200CF-501F-449E-95E4-3311D8D58A8D Q30501578-5C91518C-8E16-45F9-9240-C3A02118422D Q33596689-924FFA83-F254-4282-AD0F-4D88A993FACD Q34061632-07B3A196-6311-44DB-91DA-80DBA04AA9BA Q34553589-EE526080-7206-4703-A28D-D22E88E2241B Q34883178-E6D6C044-24D8-4C3F-B431-09874C8C2B5D Q35247511-4226C80E-A0AC-4065-BB23-01DE6EA2B249 Q35635580-B7E3AD8B-C534-45DF-867C-ED555EC45286 Q35665871-2AEAB302-C607-4C1A-9394-C66192C40AF2 Q36309032-66AC8C43-C2F4-4AAA-A1F3-E6291A9103A2 Q36433306-84863D0A-F858-4202-AF7C-13F7F2DA2E7F Q36509288-4E6DDFC0-56C8-4CEE-B5AB-404CEF01D7DC Q36822452-102783BD-34CE-40E0-8EC6-CB6F80302916 Q36854195-49A48A19-AB77-46EF-B69B-2861771E0F25 Q36951447-BE12B901-4169-4FA6-A311-ABCA01D5A360 Q36995447-631705A2-9817-4047-9851-9F7D3D5EDEB4 Q37007821-4155EB41-D9CC-4EAF-B572-676392D127C8 Q37109593-E7F127A7-A471-4BE3-A06C-999093070412 Q37109597-8F16F1DF-4E1E-462A-AEC1-780E4501255D Q37127636-59DB9023-2928-4023-9664-0CD609272257 Q37265117-BE9B93CC-58BB-4CC5-B07D-23584C55CB8B Q37290507-7D6AFAE9-4F0B-41C8-BB77-BDC67AB244EA Q37350401-F5A2BAB4-FFE3-467B-AD54-D456FCFFF439 Q37534497-90601DAE-507A-4655-8C91-4924C15791A4 Q37775790-12775AE5-07D8-4F78-B562-B4DF2614F03A Q37801828-ACD3F428-263A-4429-AAEA-A9AE3BAA3028 Q37813149-C6E6C83C-B60F-4EF9-A400-C46AE85D65FE Q37950838-AFE96F7D-A000-4C7B-91FB-B6BFC47CD703 Q37994740-0B005178-38AF-4785-8B88-39E4572A6D19 Q38184922-C0C0B994-9D0C-4AAB-B59D-B44B00B6E56F Q38252008-F9E0D7E1-7C9F-4A69-A362-DF388645EC81 Q38264149-5F074C37-A0B1-44AE-B992-4E88F868B0A7 Q38558725-0D2AB1EF-8562-4E57-9C0A-4D176AE209A0 Q41172322-FA5D499A-36C7-4586-8B87-A5BF0E9BF30C Q41570414-E8E456CD-CBA9-42EC-8533-1676B53B2509

P2860

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

http://www.wikidata.org/entity/Q52007706

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@en

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@nl

type

label

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@en

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@nl

prefLabel

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@en

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@nl

P1433

Q52007706-B4FAFEB7-2EFB-4159-AF13-64635EA6DAAE

P1476

Q52007706-34026717-934C-4775-8704-66866161BA48

P2093

Q52007706-02F2F0AF-52FF-4665-BFA4-217D0D4DED74

Q52007706-09D62D0C-ACC6-46A9-A376-31D8C5A3995E

Q52007706-0A7F04D3-647D-4F7E-86FB-E199A7C26558

Q52007706-394054B7-CF00-4BFF-BBA4-5565DF78ABD5

Q52007706-411FDF47-34C5-4AC8-88E4-08DE9650B5CC

Q52007706-5230D1EC-7B11-42EB-8385-BAEA28ADD3F7

Q52007706-5C61B1F4-809B-48A9-8DCF-993B662BAAB8

Q52007706-9C3D6CA9-5B17-4032-917F-CFB1AC2C9541

Q52007706-E2EEE1BB-9178-48D8-BA7B-71458CA6552E

Q52007706-E3615B9D-8502-4270-9488-64B585597CF8

P304

Q52007706-B85B7D44-8E32-4364-97FD-8F7233F257BE

P31

Q52007706-E9785EFE-28E6-413F-BEAA-B0BA360679E2

P356

Q52007706-05E96D12-0AC0-44CB-82C0-974792E5436E

P407

Q52007706-BE800DCF-2F0B-4A84-8FBA-93B529185618

P433

Q52007706-FA38B4B3-067B-491F-A2B7-920B50D99D9B

P478

Q52007706-15502BB2-C092-44F9-8C97-2B71CA257B9E

P50

Q52007706-AB43B2FB-F882-4EB0-AFFC-5E2398C48A70

Q52007706-D85B818A-2304-4296-8B00-B07A81B8AF4D

P577

Q52007706-F1B30493-2EA1-4838-8B66-F4FA69B93CAD

P5875

Q52007706-BED2325C-F312-490E-80ED-44C53EF10D9C

P698

Q52007706-CA5D1643-CC91-40D8-BD61-AD436E35682B

P921

Q52007706-D2BD26F3-BC34-4049-8EFB-DD0587AFC355

P356

P1433

P1476

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

@en

P2093

Catharina Whybra

http://www.w3.org/2001/XMLSchema#string

Chevalia Robinson

http://www.w3.org/2001/XMLSchema#string

Christoph Kampmann

http://www.w3.org/2001/XMLSchema#string

Gregory Pastores

http://www.w3.org/2001/XMLSchema#string

Joe T R Clarke

http://www.w3.org/2001/XMLSchema#string

Margaret Timmons

http://www.w3.org/2001/XMLSchema#string

Michael Beck

http://www.w3.org/2001/XMLSchema#string

Raphael Schiffmann

http://www.w3.org/2001/XMLSchema#string

Roscoe O Brady

http://www.w3.org/2001/XMLSchema#string

Y Howard Lien

http://www.w3.org/2001/XMLSchema#string

P304

924-932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2005-2895

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Bradley L. Schlaggar

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6838955

http://www.w3.org/2001/XMLSchema#string

P698

16950982

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy